humira
abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - molimo pogledajte dokument s informacijama o proizvodu.
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
lupron depo 11,25 mg prašak i otapalo za suspenziju za injekciju u napunjenoj štrcaljki
abbvie d.o.o., strojarska cesta 20, zagreb, hrvatska - leuprorelinum - prašak i otapalo za suspenziju za injekciju u napunjenoj štrcaljki - 11,25 mg - urbroj: jedna napunjena štrcaljka sadrži 11,25 mg leuprorelinacetata
lupron depo 3,75 mg prašak i otapalo za suspenziju za injekciju u napunjenoj štrcaljki
abbvie d.o.o., strojarska cesta 20, zagreb, hrvatska - leuprorelinum - prašak i otapalo za suspenziju za injekciju u napunjenoj štrcaljki - 3,75 mg - urbroj: jedna napunjena štrcaljka sadrži 3,75 mg leuprorelinacetata
zemplar 5 mikrograma/ml otopina za injekciju
abbvie d.o.o., strojarska 20, zagreb - parikalcitol - otopina za injekciju - 5 mikrograma/ml - urbroj: 1 ml otopine za injekciju sadrži 5 mikrograma parikalcitola
survanta 25 mg/1 ml suspenzija za endotraheopulmonalno ukapavanje
abbvie d.o.o. - esencijalni fosfolipidi - suspenzija za endotraheopulmonalno ukapavanje - 25 mg/1 ml - 1 ml suspenzije sadrži: 25 mg ukupnih fosfolipida
survanta 25 mg/1 ml suspenzija za endotraheopulmonalno ukapavanje
abbvie d.o.o. - esencijalni fosfolipidi - suspenzija za endotraheopulmonalno ukapavanje - 25 mg/1 ml - 1 ml suspenzije sadrži: 25 mg ukupnih fosfolipida
norvir 100 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - ritonavir - filmom obložena tableta - 100 mg/1 tableta - 1 filmom obložena tableta sadrži: 100 mg ritonavir
humira 40 mg/0.8 ml otopina za injekciju
abbvie d.o.o. - adalimumab - otopina za injekciju - 40 mg/0.8 ml - 0,8 ml otopine za injekciju sadrži: 40 mg adalimumaba
lucrin depot pds 3.75 mg/1 šprica prašak i rastvarač za suspenziju za injekciju s produženim oslobađanjem
abbvie d.o.o. - лейпрорелин - prašak i rastvarač za suspenziju za injekciju s produženim oslobađanjem - 3.75 mg/1 šprica - 1 napunjena šprica sa praškom i rastvaračem za suspenziju za injekciju s produženim oslobađanjem sadrži: 3,75 mg leuprorelina (u obliku leuprorelin acetata)